Harrow jumps on predicting Q4 sales above estimate

** Harrow HROW soars ~24% to $28.90 premarket

** Eye-drug maker sees prelim Q4 sales in the $65 mln-$67 mln range; analysts' estimate stands at $58.4 mln, per data compiled by LSEG

** Forecasts 2025 sales to be more than $280 mln, slightly below analysts' estimate of $281.2 mln

** Expects its FDA-approved, high-profit branded products to be the main driver of growth this year

** HROW gained ~181% in 2024